Aliases & Classifications for Purpura

MalaCards integrated aliases for Purpura:

Name: Purpura 12 75 55 44 15 72
Purpuric Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3326
MeSH 44 D011693
NCIt 50 C78787
SNOMED-CT 68 12393003
ICD10 33 D69.2
UMLS 72 C0034150

Summaries for Purpura

MalaCards based summary : Purpura, also known as purpuric disorder, is related to thrombocytopenic purpura, autoimmune and thrombotic thrombocytopenic purpura, and has symptoms including pruritus, hemoptysis and flushing. An important gene associated with Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are TGF-Beta Pathway and Phospholipase-C Pathway. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and bone marrow, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 75 Purpura is a condition of red or purple discolored spots on the skin that do not blanch on applying... more...

Related Diseases for Purpura

Diseases related to Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1460)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenic purpura, autoimmune 34.2 THPO MPL ITGB3 ITGA2B
2 thrombotic thrombocytopenic purpura 34.2 VWF THBD F3 APOH ADAMTS13
3 purpura fulminans 33.1 SERPINC1 PROS1 PROCR PROC F3 F2
4 protein c deficiency 32.7 THBD SERPINC1 PROC F2
5 thrombocytopenia due to platelet alloimmunization 32.6 THPO MPL ITGB3 ITGA2B ITGA2
6 fetal and neonatal alloimmune thrombocytopenia 32.3 ITGB3 ITGA2B ITGA2
7 protein s deficiency 32.0 SERPINC1 PROS1 F3 F2 APOH
8 adult-onset still's disease 32.0 TNF IL6 CRP
9 proteasome-associated autoinflammatory syndrome 1 31.7 TNF IL6 CRP
10 iga glomerulonephritis 31.5 IL6 CD79A CD40LG
11 autoimmune disease 31.4 TNF IL6 CD40LG APOH
12 von willebrand's disease 31.4 VWF F3 F2 ADAMTS13
13 hemolytic-uremic syndrome 31.4 VWF THBD F3 ADAMTS13
14 qualitative platelet defect 31.3 VWF F3 F2
15 heparin-induced thrombocytopenia 31.2 SERPINC1 F3 CD79A CD40LG
16 disseminated intravascular coagulation 31.2 THBD SERPINC1 F3 F2 ADAMTS13
17 toxic shock syndrome 31.1 TNF SERPINC1 IL6
18 exanthem 31.1 TNF IL6 CRP
19 hemolytic uremic syndrome, atypical 1 31.0 VWF THBD ADAMTS13
20 hemophilia b 30.9 SERPINC1 F3 F2
21 antithrombin iii deficiency 30.9 SERPINC1 F2 APOH
22 raynaud phenomenon 30.9 VWF THBD APOH
23 factor xii deficiency 30.9 SERPINC1 F3 APOH
24 hemophilia 30.8 VWF F3 F2
25 cryofibrinogenemia 30.8 CD79A CD40LG
26 tonsillitis 30.7 TNF IL6 CD79A
27 intussusception 30.7 IL6 CRP CD40LG
28 factor xi deficiency 30.6 THBD SERPINC1 F3 F2
29 catastrophic antiphospholipid syndrome 30.6 PROC F3 CD40LG APOH ADAMTS13
30 factor x deficiency 30.6 VWF SERPINC1 F3 F2
31 factor v deficiency 30.5 VWF F3 F2
32 hypersplenism 30.5 THPO SERPINC1 F2
33 syphilis 30.5 CD79A CD40LG APOH
34 mixed connective tissue disease 30.5 TNF IL6 APOH ADAMTS13
35 meningoencephalitis 30.5 IL6 CD79A CD40LG
36 connective tissue disease 30.5 TNF IL6 CD40LG APOH ADAMTS13
37 meningococcemia 30.4 THBD SERPINC1 PROCR PROC
38 myocarditis 30.4 TNF IL6 CD40LG
39 adult respiratory distress syndrome 30.4 TNF IL6 F2
40 otitis media 30.4 TNF IL6 CD79A
41 von willebrand disease, type 1 30.4 VWF F3 F2
42 end stage renal failure 30.4 TNF IL6 CRP
43 eclampsia 30.4 TNF THBD SERPINC1 F2
44 thrombophlebitis 30.3 SERPINC1 F2 APOH
45 liver cirrhosis 30.3 THPO SERPINC1 F3 F2
46 prothrombin deficiency, congenital 30.3 SERPINC1 F2 APOH
47 common variable immunodeficiency 30.3 TNF IL6 CD79A CD40LG
48 c1q nephropathy 30.3 CD79A CD40LG
49 vasculitis 30.2 VWF TNF THBD CRP CD40LG APOH
50 portal vein thrombosis 30.2 SERPINC1 F2 APOH

Graphical network of the top 20 diseases related to Purpura:



Diseases related to Purpura

Symptoms & Phenotypes for Purpura

UMLS symptoms related to Purpura:


pruritus, hemoptysis, flushing, icterus, petechiae of skin, skin manifestations, integumentary system signs and symptoms

MGI Mouse Phenotypes related to Purpura:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ADAMTS13 APOH CD40LG CD79A CRP F2
2 hematopoietic system MP:0005397 10.39 ADAMTS13 CD40LG CD79A F2 F3 IL6
3 cardiovascular system MP:0005385 10.34 CD40LG CRP F2 F3 IL6 ITGA2B
4 immune system MP:0005387 10.3 ADAMTS13 CD40LG CD79A CRP F2 F3
5 cellular MP:0005384 10.22 CD40LG CD79A F3 IL6 ITGA2 ITGA2B
6 embryo MP:0005380 10.16 F2 F3 ITGA2B ITGB3 MPL PROCR
7 mortality/aging MP:0010768 10.03 ADAMTS13 APOH CD40LG F2 F3 IL6
8 integument MP:0010771 9.97 CD40LG F2 F3 IL6 ITGA2 ITGB3
9 liver/biliary system MP:0005370 9.86 CD79A IL6 ITGB3 PROC PROS1 SERPINC1
10 nervous system MP:0003631 9.73 CD40LG CD79A F2 F3 IL6 ITGB3
11 normal MP:0002873 9.28 ADAMTS13 CD79A F2 F3 ITGA2 ITGB3

Drugs & Therapeutics for Purpura

Drugs for Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
6
rituximab Approved Phase 4 174722-31-7 10201696
7
alemtuzumab Approved, Investigational Phase 4 216503-57-0
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
leucovorin Approved Phase 4 58-05-9 143 6006
10
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
11
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
12
Clarithromycin Approved Phase 4 81103-11-9 84029
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Caffeic acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 1549111
17
Enoxolone Investigational Phase 4 471-53-4 18526330
18 Antiprotozoal Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Tubulin Modulators Phase 4
21 Antimitotic Agents Phase 4
22 Antimalarials Phase 4
23 Retinol palmitate Phase 4
24 retinol Phase 4
25 Antineoplastic Agents, Phytogenic Phase 4
26 Arnica Phase 4
27 Calcium, Dietary Phase 4
28 Antibodies Phase 4
29 Immunologic Factors Phase 4
30 Immunoglobulins Phase 4
31 Antineoplastic Agents, Immunological Phase 4
32 Dermatologic Agents Phase 4
33 Immunosuppressive Agents Phase 4
34 Cyclosporins Phase 4
35 Antilymphocyte Serum Phase 4
36 Antimetabolites Phase 4
37 Antimetabolites, Antineoplastic Phase 4
38 Bone Density Conservation Agents Phase 4
39 Nucleic Acid Synthesis Inhibitors Phase 4
40 Folic Acid Antagonists Phase 4
41 Vitamin B9 Phase 4
42 Vitamin B Complex Phase 4
43 Folate Phase 4
44 Cytochrome P-450 CYP3A Inhibitors Phase 4
45 Cytochrome P-450 Enzyme Inhibitors Phase 4
46 Omega 3 Fatty Acid Phase 4
47
Dapsone Approved, Investigational Phase 3 80-08-0 2955
48
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
49
Acetaminophen Approved Phase 3 103-90-2 1983
50
Chlorpheniramine Approved Phase 3 132-22-9, 113-92-8 2725

Interventional clinical trials:

(show top 50) (show all 435)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
4 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
5 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
6 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
7 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
8 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
9 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
10 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
11 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
12 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
13 Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula
14 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
15 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
16 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Recruiting NCT03784898 Phase 4
17 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
18 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
19 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
20 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
21 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
22 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
23 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
24 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
25 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Active, not recruiting NCT02760251 Phase 4 romiplostim
26 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
27 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Not yet recruiting NCT03866798 Phase 4
28 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
29 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
30 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
31 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
32 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
33 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
34 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
35 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
36 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
37 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
38 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
39 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
40 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
41 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
42 An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT01071954 Phase 3
43 A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00603642 Phase 3 Placebo;AMG 531
44 A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura Completed NCT00770562 Phase 3 rituximab;Dexamethasone
45 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets
46 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
47 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
48 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
49 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects With Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study> Completed NCT00540423 Phase 3 SB-497115-GR 12.5mg;SB-497115-GR 25mg;SB-497115-GR 12.5mg matching placebo;SB-497115-GR 50 mg
50 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP

Search NIH Clinical Center for Purpura

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Epoprostenol
Epoprostenol Sodium
Plasma protein fraction (human)

Cochrane evidence based reviews: purpura

Genetic Tests for Purpura

Anatomical Context for Purpura

MalaCards organs/tissues related to Purpura:

41
Skin, Bone, Bone Marrow, Spleen, T Cells, Kidney, Liver

Publications for Purpura

Articles related to Purpura:

(show top 50) (show all 21954)
# Title Authors PMID Year
1
Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. 9 38
20056836 2010
2
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report. 9 38
20181224 2010
3
[Henoch-Shönlein purpura]. 9 38
19345173 2009
4
Childhood Henoch-Schonlein nephritis: a multivariate analysis of clinical features and renal morphology at disease onset. 9 38
19377254 2009
5
Vasculitic IgA nephropathy: prognosis and outcome. 9 38
19342865 2009
6
Familial clusturing of Henoch-Schönlein purpura or IgA nephropathy: genetic background or environmental triggers? 9 38
19067882 2008
7
IgA nephropathy and Henoch-Schönlein purpura nephritis. 9 38
18332712 2008
8
The diagnostic value of IgA deposition in Henoch-Schönlein purpura. 9 38
18304186 2008
9
Splenic peliosis in the course of IgA nephropathy. 9 38
17885767 2007
10
Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. 9 38
17551657 2007
11
Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. 9 38
17699418 2007
12
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 9 38
17164950 2006
13
Fatal relapse of thrombotic thrombocytopaenic purpura after cardiac surgery in patient with congenital absence of vWF-cleaving protease activity. 9 38
16421154 2006
14
Thrombotic thrombocytopaenic purpura in HIV-infected patients. 9 38
16105187 2005
15
[Effect of danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis]. 9 38
14714360 2003
16
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. 9 38
12656756 2003
17
Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. 9 38
12453297 2002
18
Acute glomerulonephritis. 9 38
10798062 1999
19
IgA nephropathy--human disease and animal model. 9 38
9154653 1997
20
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. 9 38
9126006 1997
21
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis. 9 38
9046734 1997
22
Inherited prethrombotic disorders and infectious purpura. 9 38
8822583 1996
23
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. 9 38
8639762 1996
24
IgA-associated renal diseases. 9 38
8744534 1996
25
Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. 9 38
8503268 1993
26
Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura. 9 38
1445457 1992
27
Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. 9 38
1430582 1992
28
Regional variation in C4 phenotype in patients with IgA nephropathy. 9 38
2329414 1990
29
[Schönlein-Henoch purpura and IgA nephropathy. A common pathogenetic cause?]. 9 38
2327670 1990
30
Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts. 38
31359341 2019
31
Posterior reversible encephalopathy syndrome and intracerebral hemorrhage in an adult patient with Henoch-Schönlein purpura. 38
31368450 2019
32
Serum level of advanced oxidation protein products (AOPPs) in patients with Henoch-Schonlein purpura and its relationship with aberrant glycosylation of IgA1 and Cosmc mRNA expression. 38
31250447 2019
33
Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura. 38
31340669 2019
34
Caplacizumab for relapsing thrombotic thrombocytopenic purpura. 38
31177334 2019
35
Fatigue and cognitive impairment in immune thrombocytopenic purpura remain stable over time: short report from a longitudinal study. 38
31119732 2019
36
Necrotic leg ulcers secondary to hydrophilic polymer gel emboli. 38
31334407 2019
37
Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals. 38
31432523 2019
38
HIV-associated thrombotic thrombocytopaenic purpura: A retrospective cohort study during the anti-retroviral therapy era. 38
30758877 2019
39
Exploration of susceptible genes associated with Henoch-Schönlein purpura by whole exome sequencing. 38
31430067 2019
40
50 Years Ago in TheJournal ofPediatrics: Anaphylactoid Purpura: Streptococcal Antibody Titers and β1c-Globulin Levels. 38
31349913 2019
41
Rituximab associated vasculitis flare: incidence, predictors and outcome. 38
31371658 2019
42
Pregnancy of Patients with Idiopathic Thrombocytopenic Purpura: Maternal and Neonatal Outcomes 38
31397144 2019
43
Immune Thrombocytopenic Purpura in Pregnancy. 38
31418451 2019
44
Predictive markers of lymphomagenesis in Sjögren's syndrome: From clinical data to molecular stratification. 38
31431317 2019
45
The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. 38
31102993 2019
46
New insights in cryoglobulinemic vasculitis. 38
31383568 2019
47
Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia. 38
30927247 2019
48
Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity. 38
30470618 2019
49
The Clinicopathological Characteristics of Henoch-Schönlein Purpura Nephritis with Presentation of Nephrotic Syndrome. 38
31387105 2019
50
Role of p300 in the pathogenesis of Henoch-Schonlein purpura nephritis and as a new target of glucocorticoid therapy in mice. 38
31365430 2019

Variations for Purpura

Expression for Purpura

Search GEO for disease gene expression data for Purpura.

Pathways for Purpura

Pathways related to Purpura according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 TNF THPO MPL ITGB3 ITGA2B ITGA2
2
Show member pathways
12.99 THPO ITGB3 ITGA2B ITGA2 IL6 CD79A
3
Show member pathways
12.92 VWF TNF ITGB3 ITGA2B ITGA2 IL6
4
Show member pathways
12.83 TNF ITGB3 ITGA2B ITGA2 F2 CD79A
5
Show member pathways
12.75 THBD SERPINC1 PROS1 PROC F3 F2
6
Show member pathways
12.55 VWF THPO THBD SERPINC1 PROS1 PROCR
7
Show member pathways
12.33 THPO ITGB3 ITGA2B ITGA2 IL6
8
Show member pathways
12.26 TNF IL6 F2 CRP
9
Show member pathways
12.16 THBD PROS1 PROCR PROC ITGB3 F2
10
Show member pathways
12.14 TNF ITGB3 ITGA2B ITGA2 IL6
11
Show member pathways
12.08 VWF ITGB3 ITGA2B ITGA2
12
Show member pathways
12.06 VWF THBD SERPINC1 PROS1 PROCR PROC
13 12.02 TNF THBD ITGB3 ITGA2B
14 11.95 VWF ITGB3 ITGA2B ITGA2
15 11.9 VWF THBD SERPINC1 PROS1 PROCR PROC
16 11.84 TNF THBD IL6 F3
17
Show member pathways
11.84 VWF THPO MPL ITGB3 ITGA2B F2
18 11.79 TNF THPO ITGB3 ITGA2B ITGA2 IL6
19 11.78 VWF ITGB3 F3
20 11.76 ITGB3 ITGA2B ITGA2
21 11.69 TNF THBD IL6
22 11.66 TNF ITGB3 IL6
23 11.66 THPO ITGB3 ITGA2B ITGA2 IL6
24 11.62 TNF THPO MPL ITGB3 ITGA2B ITGA2
25
Show member pathways
11.59 TNF IL6 CD40LG
26 11.54 ITGB3 ITGA2B ITGA2
27 11.51 VWF ITGB3 ITGA2B ITGA2 F2
28 11.46 TNF IL6 CD40LG
29 11.45 ITGB3 ITGA2B IL6
30 11.34 ITGB3 ITGA2B ITGA2 IL6
31 10.97 TNF IL6 CRP
32 10.9 TNF THPO ITGB3 ITGA2B ITGA2 IL6
33 10.85 PROS1 PROC F2
34 10.78 VWF ITGA2

GO Terms for Purpura

Cellular components related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 TNF THPO THBD SERPINC1 PROS1 PROCR
2 endoplasmic reticulum lumen GO:0005788 9.77 SERPINC1 PROC IL6 F2 ADAMTS13
3 external side of plasma membrane GO:0009897 9.73 TNF ITGA2B ITGA2 F2 CD79A CD40LG
4 blood microparticle GO:0072562 9.71 SERPINC1 PROS1 ITGA2B F2
5 integrin complex GO:0008305 9.5 ITGB3 ITGA2B ITGA2
6 cell surface GO:0009986 9.36 TNF THBD PROCR MPL ITGB3 ITGA2B
7 plasma membrane GO:0005886 10.25 TNF THBD SERPINC1 PROS1 PROCR MPL
8 extracellular region GO:0005576 10 VWF TNF THPO SERPINC1 PROS1 PROCR

Biological processes related to Purpura according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.91 SERPINC1 PROC IL6 F2
2 extracellular matrix organization GO:0030198 9.89 VWF TNF ITGB3 ITGA2B ITGA2
3 positive regulation of protein phosphorylation GO:0001934 9.88 TNF THPO ITGB3 F2
4 integrin-mediated signaling pathway GO:0007229 9.83 ITGB3 ITGA2B ITGA2 ADAMTS13
5 cell-matrix adhesion GO:0007160 9.81 ITGB3 ITGA2B ITGA2 ADAMTS13
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF ITGA2 IL6
7 platelet degranulation GO:0002576 9.77 VWF PROS1 ITGB3 ITGA2B APOH
8 platelet aggregation GO:0070527 9.73 MPL ITGB3 ITGA2B
9 platelet activation GO:0030168 9.73 VWF ITGB3 IL6 F2 CD40LG ADAMTS13
10 acute-phase response GO:0006953 9.71 IL6 F2 CRP
11 cell-substrate adhesion GO:0031589 9.65 VWF ITGB3 ITGA2
12 positive regulation of leukocyte migration GO:0002687 9.64 ITGA2B ITGA2
13 positive regulation of blood coagulation GO:0030194 9.64 F2 APOH
14 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.63 ITGB3 CRP
15 mesodermal cell differentiation GO:0048333 9.63 ITGB3 ITGA2
16 blood coagulation, intrinsic pathway GO:0007597 9.63 VWF F2 APOH
17 positive regulation of positive chemotaxis GO:0050927 9.62 ITGA2 F3
18 response to amine GO:0014075 9.62 ITGA2 ADAMTS13
19 negative regulation of blood coagulation GO:0030195 9.62 THBD PROS1 PROC APOH
20 negative regulation of platelet activation GO:0010544 9.61 THBD F2
21 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
22 hemostasis GO:0007599 9.61 VWF THBD SERPINC1 PROS1 PROCR PROC
23 negative regulation of coagulation GO:0050819 9.6 PROCR PROC
24 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6
25 negative regulation of fibrinolysis GO:0051918 9.58 THBD F2 APOH
26 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
27 thrombopoietin-mediated signaling pathway GO:0038163 9.55 THPO MPL
28 negative regulation of lipid storage GO:0010888 9.46 TNF ITGB3 IL6 CRP
29 blood coagulation GO:0007596 9.36 VWF THBD SERPINC1 PROS1 PROCR PROC

Molecular functions related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 VWF TNF THBD SERPINC1 PROCR PROC
2 identical protein binding GO:0042802 9.87 VWF TNF SERPINC1 ITGB3 ITGA2B CRP
3 calcium ion binding GO:0005509 9.85 THBD PROS1 PROC F2 CRP ADAMTS13
4 cytokine activity GO:0005125 9.71 TNF THPO IL6 CD40LG
5 integrin binding GO:0005178 9.46 VWF ITGB3 ITGA2 ADAMTS13
6 fibrinogen binding GO:0070051 9.26 ITGB3 ITGA2B
7 protease binding GO:0002020 9.02 VWF TNF SERPINC1 ITGB3 F3

Sources for Purpura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....